Supernus Pharmaceuticals Inc
LSE:0LB2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Supernus Pharmaceuticals Inc
LSE:0LB2
|
US |
|
Mitsubishi Corp
F:MBI0
|
JP |
|
Dexerials Corp
OTC:DEXCF
|
JP |
|
Cullen/Frost Bankers Inc
NYSE:CFR
|
US |
|
D
|
Dollar Tree Inc
F:DT3
|
US |
|
B
|
BYD Co Ltd
XHAM:BY6
|
CN |
|
L
|
Lanxess AG
XMUN:LXS
|
DE |
|
S
|
Supernus Pharmaceuticals Inc
SWB:S49
|
US |
|
Telus International Cda Inc
TSX:TIXT
|
CA |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
US |
|
I
|
Intellego Technologies AB
STO:INT
|
SE |
|
Cadeler A/S
OSE:CADLR
|
DK |
|
S
|
Sturm Ruger & Company Inc
SWB:ST2
|
US |
|
D
|
Dominion Energy Inc
DUS:DOD
|
US |
|
G
|
G8 Education Ltd
F:3EAG
|
AU |
Wall St Price Targets
0LB2 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 0LB2 is 65.55 USD with a low forecast of 56.22 USD and a high forecast of 71.2 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0LB2's stock price target?
Price Target
65.55
USD
According to Wall Street analysts, the average 1-year price target for 0LB2 is 65.55 USD with a low forecast of 56.22 USD and a high forecast of 71.2 USD.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.
